Genix Pharmaceuticals Corp
XTSX:GENX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Genix Pharmaceuticals Corp
Income from Continuing Operations
Genix Pharmaceuticals Corp
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genix Pharmaceuticals Corp
XTSX:GENX
|
Income from Continuing Operations
-CA$335.1k
|
CAGR 3-Years
32%
|
CAGR 5-Years
14%
|
CAGR 10-Years
5%
|
|
|
Flora Growth Corp
NASDAQ:FLGC
|
Income from Continuing Operations
-$15.9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
N/A
|
|
|
Vitality Products Inc
XTSX:VPI
|
Income from Continuing Operations
-CA$48.9k
|
CAGR 3-Years
55%
|
CAGR 5-Years
24%
|
CAGR 10-Years
14%
|
|
|
Jamieson Wellness Inc
TSX:JWEL
|
Income from Continuing Operations
CA$64.5m
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
L
|
Leef Brands Inc
CNSX:LEEF
|
Income from Continuing Operations
-$20.7m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
Genix Pharmaceuticals Corp
Glance View
Genix Pharmaceuticals Corp. engages in the the research, development, manufacture, licensing and sales of novel and innovative healthcare products, particularly proprietary over the counter nutraceuticals and generic pharmaceuticals. The company is headquartered in Vancouver, British Columbia. The firm focused on developing and licensing novels and products for sales through retail outlets and well as direct to consumers and e-commerce platforms. The firm holds licensing agreement for a range of products, including 30 Ophthalmic drugs, Sucanon, Renochlor, Flu-X, and Levothyroxine sodium (generic Synthroid). Flu-X anti-viral spray is an herbal, oral, anti-viral, anti-flu and anti-cold virus spray. Renochlor is an aid in the restoration of kidney health and kidney function. Sucanon is a natural substitute for prescription pharmaceuticals for non-insulin dependent diabetes patients.
See Also
What is Genix Pharmaceuticals Corp's Income from Continuing Operations?
Income from Continuing Operations
-335.1k
CAD
Based on the financial report for Oct 31, 2025, Genix Pharmaceuticals Corp's Income from Continuing Operations amounts to -335.1k CAD.
What is Genix Pharmaceuticals Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
5%
Over the last year, the Income from Continuing Operations growth was -358%. The average annual Income from Continuing Operations growth rates for Genix Pharmaceuticals Corp have been 32% over the past three years , 14% over the past five years , and 5% over the past ten years .
